Vaccinex, Inc.

96 articles with Vaccinex, Inc.

• Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease

  3/23/2023

  Vaccinex, Inc. today announced its COO and Senior Vice President, Discovery and Translational Medicine, Elizabeth Evans, PhD, will be making a podium presentation at the AAIC Advancements: Immunity conference.

• Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  3/21/2023

  Vaccinex, Inc. today announced the initiation of a single-arm open label, Phase Ib/2 study to evaluate pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma (PDAC), NCT05102721.

• Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

  3/9/2023

  Vaccinex, Inc. (Nasdaq: VCNX) today reported that it has enrolled 36 subjects in the open-label, Phase 1b/2 KEYNOTE-B84 study (NCT04815720) to evaluate first line therapy of pepinemab in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in immunotherapy naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

• Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology

  1/9/2023

  Vaccinex, Inc. today announced that its licensee, Surface Oncology (NASDAQ: SURF, “Surface”) dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s ActivMAb.

• Vaccinex Announces $3.8 Million Private Placement

  11/28/2022

  Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that on November 23, 2022, the company closed the private placement of an aggregate of 7,142,496 shares of its common stock at a purchase price of $0.5293 per share for aggregate gross proceeds of approximately $3.8 million.

• Vaccinex Reports Third Quarter 2022 Results and Provides Corporate UpdateContinued Progress in Pepinemab Oncology and Neurology Clinical Programs

  11/14/2022

  Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update on key programs.

• Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

  11/10/2022

  Vaccinex, Inc. and its collaborators at Emory University and the Moffitt Cancer Center announced that two abstracts, including an oral presentation and a poster related to investigator-sponsored trials for pepinemab combinations, are being presented at The Society for Immunotherapy of Cancer's 37th Annual Meeting.

• Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs

  8/15/2022

  Vaccinex, Inc. today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update on key events since April, 2022 (the last 5 months).

• Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

  8/8/2022

  Vaccinex, Inc. (Nasdaq: VCNX), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research.

• Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

  5/25/2022

  Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, along with Elizabeth Evans, Ph.D., Chief Operating Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time.

• Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

  5/16/2022

  Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update.

• Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery

  4/25/2022

  Vaccinex, Inc. announced that it has been selected for poster presentation related to its ActivMAb technology platform during the upcoming 18th Annual PEGS Boston Conference & Expo, taking place from May 2nd to May 6th via in person and virtual attendance.

• Vaccinex Reports 2021 Financial Results and Provides Corporate Update

  3/31/2022

  Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the year ended December 31, 2021 and provided a corporate update on key events since the start of 2021.

• Vaccinex, Inc. Announces Upcoming Presentation at the 2022 AACR Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head & Neck Cancer

  3/9/2022

  Vaccinex, Inc. announced that it has been selected for poster presentation related to the phase 1b segment of its KEYNOTE-B84 study of pepinemab in combination with KEYTRUDA in patients with recurrent or metastatic head and neck cancer during the upcoming 2022 American Association for Cancer Research Meetings, taking place from April 8th to April 13th in New Orleans via in person and virtual attendance.

• Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting

  2/24/2022

  Vaccinex, Inc. announced that a poster will be presented at the 17th Annual HD Therapeutics Conference with its collaborator, Dr. Amber Southwell, on Wednesday, March 2, 2022.

• 

  Clinical Catch-Up: January 24 – January 28

  1/31/2022

  Clinical trial news definitely picked up this final week of January. Here’s a look.

• Vaccinex Announces $6.6 Million Private Placement

  1/27/2022

  Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022.

• Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA

  1/26/2022

  Vaccinex, Inc. today reported positive interim response data in the Phase Ib segment of the KEYNOTE-B84 study of Vaccinex’s pepinemab in combination with Merck’s anti-PD-1 therapy Keytruda.

• 

  Two Early CRs Put Vaccinex Ahead in Head and Neck Cancer

  1/26/2022

  Vaccinex announced positive interim response data in a Phase Ib study assessing pepinemab in combination with Merck’s vaunted checkpoint inhibitor, Keytruda.
• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.